A Multicenter, Open-Label Phase 1/1B Dose-Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EPHA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors

Sponsor:

MBrace Therapeutics, Inc.

Sponsor Study ID:

MBRC-101-001

CTO #:

103990

NCT Number:

NCT06014658

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder; Breast; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

Study Objectives:

To identify potential OBRD and dosing regimens of MBRC-101. To establish the MTD of MBRC-101 using 1 or more dosing regimens. To identify potential RP2Ds and regimens of MBRC-101. To evaluate the safety of MBRC-101 at potential OBRDs, RP2Ds, and dosing regimens. To evaluate preliminary clinical activity of MBRC-101.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)